

Change over 12-months of an Integrated Treatment Program for Opiate Addiction and HIV in Ho Chi Minh City, Vietnam:

# highlighting the role of counseling





T. Nguyen<sup>1,2</sup>, C.Denis<sup>3,4</sup>, A. Voisin<sup>5</sup>, T. Doan<sup>2</sup>, H. Tran<sup>2</sup>, L. Nguyen<sup>2</sup>, V. Trias<sup>2</sup>, L. Huang<sup>2</sup>, M. Auriacombe<sup>4,3</sup>, université G. Raguin<sup>2</sup>, S. Mai Thi Hoai<sup>6</sup>, G. Le Truong<sup>6</sup>, J-P. Daulouède<sup>5,4,2</sup>, C. O'Brien<sup>3</sup>, D. Metzger<sup>3,7</sup> 

<sup>1</sup>Ho Chi Minh City University of Medicine and Pharmacy; <sup>2</sup> Expertise France, Paris, France; <sup>3</sup> University of Pennsylvania, Philadelphia, PA, USA; <sup>4</sup> CNRS USR 3413 SANPsy, University of Bordeaux, Bordeaux, France; <sup>5</sup> Bizia Addiction Clinic, Bayonne, France; <sup>6</sup> HCMC Provincial AIDS Committee, Ho Chi Minh City, Vietnam; <sup>7</sup> Treatment Research Institute, Philadelphia, PA, USA

Abstract	Methods	Results (cont')	
Background: As part of the integrated drug treatment program implemented in an HIV treatment setting at Go Vap clinic, Ho Chi Minh City, Vietnam, we have developed structured counseling sessions. Methods: Participants were assessed at baseline, weekly for 12 weeks and then	<ul> <li>Efficacy of treatment at 12 months was assessed by</li> <li>Treatment retention</li> <li>Heroin use</li> </ul>	<ul> <li>Change in craving, mood, family relationships, satisfaction with income/work, satisfaction with recovery</li> </ul>	
monthly. Here we describe the retention, the treatment outcomes over the 12- month follow-up. Results: 448 heroin injectors (97.2% males, 32.3 y.o.) were enrolled (268 receiving methadone – MET, and 180 BUP/NX -Suboxone <sup>®</sup> ). The retention in	Self-reports of drug use: collected on a weekly basis for 12 weeks and monthly thereafter Urine drug screens: randomly once a week for the first 12 weeks of treatment and twice a month thereafter Agreement between self-report use and urine drug screen: high (89%)	- Significant decrease of craving regardless of the treatment (F(12,232)=20.2, p<0.0001) BUP/NX > MET	

methadone treatment at 12-month was 89.9% for MET, 57.0% for BUP/NX. Treatment adherence was high. The three treatment approaches were equally effective with a significant decrease in the days of heroin use (F(12,277)= 21.8, p<.0001) along with a significant decrease of reported craving (F(12,232)= 20.2, p<.0001), a significant improvement of mood (F(12,232)= 5.88, p<.0001), satisfaction with income/work (F(12,232)= 4.64, p<.0001), and satisfaction with recovery (F(11,249)= 3.78, p<.0001). Change in heroin use was found highly correlated with all these previously listed outcomes (correlations range: 0.20-0.72). The baseline characteristics of the participants who dropped out treatment did not differ significantly from those who completed the 12-month program. Lower self-rated mood was associated with dropping out of treatment (aOR=1.3, 95% CI=1.1-1.5), highly correlated with family relationships (p= 0.32, p< 0.0001) and satisfaction with income/work (p= 0.48, p<0.0001).

Conclusion: As part of an integrated treatment program, structured counseling sessions using both relapse prevention and cognitive-behavioral techniques that address treatment observance, substance outcomes, client's psychosocial needs and their family relationships enhance the program retention and effectiveness.

# Background

- Vietnam:
- 271,000 people using drugs (UNAIDS 2015)
- 14,000 new HIV infections in 2015, and most of them are driven by drug users
- 2006: Scale up of HIV prevention programs targeting people who inject drugs (PWID) (Giang et al., 2013)


- Self-evaluation during counseling sessions 12 weekly sessions then 10 monthly sessions thereafter - Craving
  - Mood
  - Family relationships
  - Satisfaction with income/work
  - Satisfaction with recovery
- Comparative assessments for each treatment strategies have been performed using Chi<sup>2</sup>, t-tests, and analyses of variance. Multivariable models were performed to evaluate the factors associated with retention and treatment outcomes. Spearman's correlation were used to evaluate the correlations between variables.

Results

# Participant characteristics at baseline

	All	MET	BUP/NX	Test value, p-value
	n=448	n=268	n= 180	71
Age Mean (SD)	32.6 (5.9)	32.5 (6.1)	32.7 (5.6)	t=0.52, p= 0.59
Gender – Males n (%)	434 (96.9)	260 (97.0)	174 (96.7)	$\chi^2 = 0.04, p = 0.83$
Education – High school or higher n (%)	69 (35.9)	51 (40.8)	51 (40.8)	$\chi^2=0.70, p=0.40$
Living condition	368 (82.5)	215 (80.5)	154 (86.0)	χ <sup>2</sup> =5.37, p=0.25
With parents/ family n (%)				
Currently have a job n (%)	235 (52.7)	153 (57.3)	82 (45.8)	$\chi^2 = 0.68, p = 0.02$
Serology n (%)				
HIV-positive	152 (34.2)	96 (36.0)	56 (31.5)	$\chi^2 = 0.96, p = 0.33$
Hepatitis C-positive	323 (72.4)	184 (69.0)	139 (77.7)	$\chi^2$ =4.17, p=0.05
Opiate Use				
Years of use - Mean (SD)	7.8 (6.2)	7.9 (6.9)	7.6 (4.9)	t=0.68, p=0.49
Days of use past 30 days - Mean (SD)	29.8 (1.4)	29.8 (1.2)	29.6 (1.8)	t=1.31, p=0.19
No. previous drug treatment Mean (SD)	5.4 (4.7)	5.9 (5.2)	4.6 (3.7)	t=3.14, p=0.002
Other substance use $-n$ (%) of users past 30 days				
Alcohol	86 (19.3)	48 (18.0)	38 (21.2)	$\chi^2 = 0.73$ , p=0.39
Amphet./ Methamphetamines	91 (20.4)	31 (11.6)	60 (33.5)	$\chi^2 = 31.67, p < 0.0001$
Benzodiazepines	67 (15.0)	27 (10.1)	40 (22.3)	$\chi^2 = 12.56, p = 0.0004$
Tobacco	440 (98.6)	264 (98.9)	176 (98.3)	$\chi^2 = 0.25 \text{ p} = 0.67$

- First 3 months of treatment Significant improvement of mood regardless of the treatment (F(12,232)=5.88, p<0.0001) BUP/NX > MET First 3 months of treatment - Significant improvement of satisfaction with income/work regardless of the treatment (F(12,232)=4.64, p<0.0001) - No change in family support that stayed high over the 12-month follow-up period (F(12, 232)=1.21, p=0.28) - Significant improvement of satisfaction with recovery
  - regardless of the treatment (F(11,249)=3.78, p<0.0001) BUP/NX > MET




Factors associated with dropping out treatment program Lower self-rated mood (aOR=1.3, 95% CI=1.1-1.5)


Sterile injection equipment, the introduction and expansion of methadone treatment, and increased access to antiretroviral therapy (Government of Vietnam, 2014)

- Although the proportion of HIV infections among PWID has declined from 30% in 2005 to 22% in 2013, PWID remain the largest risk group living with HIV infection (Vietnam Administration of HIV/AIDS Control, 2013)
- Since November 2013: Implementation of an integrated drug treatment program within an HIV treatment setting at Go Vap clinic, Ho Chi Minh City, Vietnam.
- Integrated Treatment provided
  - A pharmacological opiate maintenance treatment with methadone (MET) or buprenorphine/naloxone (BUP/NX)
  - Introduction of BUP/NX (Suboxone<sup>®</sup>) in January 2015
  - First time in Vietnam
  - Counseling: 12 weekly sessions and 10 monthly sessions thereafter
  - HIV screening and HIV treatment if needed
  - HCV screening
- Structured and manual-based standardized counseling sessions
  - Rooted in cognitive behavioral therapy
  - Sessions assess the need for intervention in six areas of functioning: 1) Adherence to SUD, HIV, TB; 2) continued drug use and related drug and sex risk; 3) cravings for drug use; 4) psychological status (depression, anxiety, symptoms of psychiatric disorder); 5) confidence in and satisfaction with SUD treatment; and, 6) strategies for the next month
  - Data recorded and available for review with the participant as a clinical tool to show progress and promote self-monitoring.

# Objectives



## High retention in treatment at 12 months (78.0%)



Wilcoxon chi<sup>2</sup>= 110.9, p<0.0001

6

.9)


Average daily dose (mg/day (SD)) **HIV-positive HIV-negative** All 118.5 (61.8) 163.5 (64.7) MET 101.6 (52.0)

BUP/NX daily	18.5 (5.6)	19.0 (7.4)	18.2 (4.
BUP/NX 3x/wk	14.8 (1.8)	15.1 (1.7)	14.7 (1.



Significant decrease of heroin use regardless of the treatment (F(12,277)=21.8, p<0.0001)

### BUP/NX > MET First 3 months of treatment



### Highly correlated with

First 3 months of treatment

Family relationships ( $\rho$ = 0.32, p<0.0001) Satisfaction with income/work (p=0.48, p<0.0001)

# Conclusion

- The three approaches to treatment appear to be as efficient to treat opiate use disorder
  - As part of a comprehensive and integrated treatment program i.e. OMT and structured counseling sessions

BUP/NX quit heroin earlier (within the first 3 months of Tx)

- In a context where no take-home dose is allowed, BUP/NX thrice weekly
  - Enhance retention and adherence in treatment
  - Reduce heroin use sooner
  - Less time spend traveling to and from the clinic (reduces the cost for the client)
  - Less disturbance that prevents from working (less missed time from work)
- Importance of counseling sessions that address: substance use, craving, psychological functioning, family and social relationships Enhance retention in treatment program

To describe the retention and treatment outcomes over the 12month follow-up period

Dosing schedule: All participants were required to receive their medications in directly observed dosing as Vietnamese law does not allow take-home medication.

Methadone: Daily dosing at the clinic

Buprenorphine/naloxone: Daily dosing at the clinic at the induction of treatment

After four weeks of stable dose, switch to thrice weekly dosing (if clinically possible)

- Thus, we measured the efficacy of three opiate maintenance treatment strategies: daily methadone (MET), daily buprenorphine/naloxone (BUP/NX) and thrice weekly BUP/NX

To identify the factors associated with treatment retention

### Funding: NIDA R01- DA033671

Conflict of Interest: Suboxone<sup>®</sup> tablets were donated by Reckitt-Benckiser/Indivior PLC. The pharmaceutical company has no role in study design, data collection, nor data analyses

(F(12,702)=0.69, p<0.0001)

# No change in other substance use

Change in heroin use correlated with

	MET	BUP/NX	
Craving	0.72	0.64	
Mood	0.54	0.56	
Family	0.27	0.20	
Income Satisfaction	0.30	0.31	
w/ recovery	0.56	0.52	All p<0.0001

• Not able to predict who will respond better on one medication versus another

More treatment options available, more likely one will find a more suitable treatment option

Long-acting medication within a comprehensive addiction treatment could be valuable to enhance treatment engagement, retention and adherence

### Contact

Cécile Denis, PhD	cdenis@upenn.edu
David Metzger, PhD	dsm@upenn.edu
Charles O'Brien, MD, PhD	obrien@upenn.edu